Disorders of hemostasis in iga vasculitis (Henoch–schonlein purpura) in children and their correction
Кудряшова М. А., Подчерняева Н. С., Фролкова Е. В.
Педиатрия. Журнал им. Г.Н. Сперанского
Т. 98, Вып. 4, С. 71-77
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.24110/0031-403X-2019-98-4-71-77
Аннотация:
Objective of research: To study peculiarities of various parts of hemostasis system and to evaluate efficacy of anticoagulant and antiaggregant therapy for IgA vasculitis (Henoch– Schonlein purpura) in children. Materials and methods: Retro- and prospective clinical study was performed, that included 143 patients under the age of 17 years with IgA vasculitis. The number and aggregation activity of platelets, fibrinogen concentration, levels of D-dimer, tPA, thrombomodulin, protein C, vWF: Ag, vWF activity, PAI1, PAI1 activity in the serum in disease active phase and remission period were determined. Therapy efficacy was assessed by dynamics of stopping IgA vasculitis clinical syndromes. Results: In the active period of the disease, half of the patients had signs of endothelial dysfunction, 1/3 – activation of blood coagulation, and the vast majority of patients showed a persistent decrease in fibrinolysis. The inclusion of anticoagulants and antiplatelet agents in therapy significantly
Ключевые слова:
Children; D-dimers; Fibrinogen; Hemostasis; Henoch–Schonlein purpura; Heparin; IgA vasculitis; Plasminogen activator inhibitor; Von Willebrand factor
anticoagulant agent; antigen; antithrombocytic agent; D dimer; fibrinogen; immunoglobulin A; protein C; thrombomodulin; tissue plasminogen activator; von Willebrand factor; abdominal disease; anaphylactoid purpura; arthropathy; Article; blood clotting; child; disease activity; endothelial dysfunction; fibrinogen blood level; fibrinolysis; hematologic disease; hemostasis; hemostasis disorder; human; immunoglobulin a vasculitis; major clinical study; prospective study; remission; retrospective study; skin bleeding; thrombocyte aggregation
Язык текста: Русский
ISSN: 1990-2182
Кудряшова М. А.
Подчерняева Н. С. Надежда Степановна 1957-
Фролкова Е. В. Елена Васильевна 1958-
Kudryashova M. A.
Podchernyaeva N. S. Nadezhda Stepanovna 1957-
Frolkova E. V. Elena Vasilyevna 1958-
Disorders of hemostasis in iga vasculitis (Henoch–schonlein purpura) in children and their correction
Текст визуальный непосредственный
Педиатрия. Журнал им. Г.Н. Сперанского
ООО "Педиатрия"
Т. 98, Вып. 4 С. 71-77
2019
Статья
Children D-dimers Fibrinogen Hemostasis Henoch–Schonlein purpura Heparin IgA vasculitis Plasminogen activator inhibitor Von Willebrand factor
anticoagulant agent antigen antithrombocytic agent D dimer fibrinogen immunoglobulin A protein C thrombomodulin tissue plasminogen activator von Willebrand factor abdominal disease anaphylactoid purpura arthropathy Article blood clotting child disease activity endothelial dysfunction fibrinogen blood level fibrinolysis hematologic disease hemostasis hemostasis disorder human immunoglobulin a vasculitis major clinical study prospective study remission retrospective study skin bleeding thrombocyte aggregation
Objective of research: To study peculiarities of various parts of hemostasis system and to evaluate efficacy of anticoagulant and antiaggregant therapy for IgA vasculitis (Henoch– Schonlein purpura) in children. Materials and methods: Retro- and prospective clinical study was performed, that included 143 patients under the age of 17 years with IgA vasculitis. The number and aggregation activity of platelets, fibrinogen concentration, levels of D-dimer, tPA, thrombomodulin, protein C, vWF: Ag, vWF activity, PAI1, PAI1 activity in the serum in disease active phase and remission period were determined. Therapy efficacy was assessed by dynamics of stopping IgA vasculitis clinical syndromes. Results: In the active period of the disease, half of the patients had signs of endothelial dysfunction, 1/3 – activation of blood coagulation, and the vast majority of patients showed a persistent decrease in fibrinolysis. The inclusion of anticoagulants and antiplatelet agents in therapy significantly